SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 20.35% Gain
Comtex SmarTrend(R) - Wed Aug 20, 4:00PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $5.02 to a high of $5.99. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $4.70 on volume of 33.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today
at The Street - Wed Aug 20, 9:29AM CDT
Amicus Therapeutics (FOLD) surged to a 52-week high on Wednesday after the company announced its potential Fabry disease treatment drug migalastat met its primary endpoints in a late-stage study.
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Wed Aug 20, 9:12AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amicus Therapeutics , a clinical-stage...
Amicus Therapeutics Has Returned 111.6% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Aug 20, 9:10AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on May 30th, 2014 at $2.42. In approximately 3 months, Amicus Therapeutics has returned 111.57% as of today's recent price of $5.12.
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
at The Street - Wed Aug 20, 5:01AM CDT
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
GlobeNewswire - Wed Aug 20, 5:00AM CDT
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Aug 07, 3:43PM CDT
Results From Second Phase 3 Fabry Monotherapy Study (Study 012) on Track for 3Q14
Why Amicus Therapeutics (FOLD) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 7:44AM CDT
Amicus Therapeutics possess a favorable Zacks Rank and a positive Zacks Earnings ESP
Amicus Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:00PM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, August 7, 2014 at 5:00 p.m. ET to discuss financial results for the second quarter ended June 30, 2014.
Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
PR Newswire - Wed Jul 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Medivation, Inc. (NASDAQ: MDVN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5255-100free.
Amicus (FOLD) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:11AM CDT
Amicus (FOLD) Shares March Higher, Can It Continue?
Applied Genetic Technologies Corporation (AGTC) Looks Strong as Stock Surges 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:44AM CDT
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares shoot up over 15% on the day.
Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:44AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.
Amicus Therapeutics (FOLD) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 7% on the day.
Hot Stock: Amicus Therapeutics, Shares Gain 9.1% (FOLD)
Comtex SmarTrend(R) - Wed Jul 23, 12:43PM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 9.1% to $4.18 on 1.1x average daily volume. Amicus Therapeutics has traded 2.2 million shares thus far today, vs. average volume of 2.0 million shares per day. The stock has outperformed the Dow (9.1% to the Dow's -0.2%) and outperformed the S&P 500 (9.1% to the S&P's 0.2%) during today's trading.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
Amicus Therapeutics Analyst Report; Solid Pipeline and Near-term Catalysts by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 07, 1:55PM CDT
Lysosomal storage disorders are a group of approximately 50 rare inherited metabolic disorders resulting from defects in lysosomal function. These severe, chronic genetic diseases have unmet medical needs, and include Fabry disease, Gaucher disease, Parkinson's disease, Pompe disease, and Tay-Sachs disease. The market for current drug therapies to address these disorders is estimated to exceed $3 billion.
Can the Uptrend Continue for Amicus (FOLD)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:33AM CDT
Can the Uptrend Continue for Amicus (FOLD)?